United States

IDBiologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19

Lead Product(s): Monoclonal antibody

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Vanderbilt University Medical Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2020

Details:

For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.

Atreca

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

Lead Product(s): IgM antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: BeiGene

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 29, 2020

Details:

The companies will leverage their combined technology in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19.

ImmunoPrecise

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens

Lead Product(s): Monocloncal antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: State of North Dakota

Deal Size: $0.1 million Upfront Cash: Undisclosed

Deal Type: Funding April 24, 2020

Details:

The State of North Dakota has provided ImmunoPrecise grant for the development of a novel platform for the rapid development of COVID-19 drugs and other emerging pathogens.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics, Voltron Therapeutics & HaloVax Announce Selection of First of Virus Targeting Peptides in Development of COVID-19 Vaccine

Lead Product(s): Self-Assembling Vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Candidate selected to initiate testing of HaloVax™, a Self-Assembling Vaccine to protect people at risk of COVID-19 infection .

Q BioMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics

Lead Product(s): COVID-19 drug

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 22, 2020

Details:

The Joint venture will deploy Cyclica's unique AI platform to accelerate the development of new treatments based on Mannin's Tie2 based platform.

Applied Biology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Applied Biology to License Intellectual Property Rights to a Novel Cannabinoid Based Therapy Under Development for COVID-19

Lead Product(s): Cannabinoids

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

On the heels of discovering an association between covid-19 and androgens, applied biology to expand its research program into anti-androgen based therapies.

Applied Biology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery

Lead Product(s): Androgens

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2020

Details:

Drug discovery platform to rapidly predict blocking of covid-19 pneumocyte cellular entry.

Scripps Research

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS

Lead Product(s): SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2020

Details:

The study, published in Science, is the first to map a human antibody’s interaction with the new coronavirus at near-atomic-scale resolution.

Adaptive Biotechnologies

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

Lead Product(s): Human neutralizing antibodies

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership April 02, 2020

Details:

The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.

Applied DNA Sciences Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate

Lead Product(s): DNA vaccine

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Discovery Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

Details:

The newly added 5th linear DNA vaccine candidate encodes an engineered fusion protein of a COVID-19 Spike domain with an immunomodulator moiety.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

IDBiologics

Vanderbilt University Medical Center and IDBiologics Ally in Race to Develop Breakthrough Medicines for COVID-19

Atreca

Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody Treatment for COVID-19

ImmunoPrecise

ImmunoPrecise Awarded Grant Focused on Coronavirus and Other Emerging Pathogens

Hoth Therapeutics

Hoth Therapeutics, Voltron Therapeutics & HaloVax Announce Selection of First of Virus Targeting Peptides in Development of COVID-19 Vaccine

Q BioMed

Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics

Applied Biology

Applied Biology to License Intellectual Property Rights to a Novel Cannabinoid Based Therapy Under Development for COVID-19

Applied Biology

Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery

Scripps Research

Clues to COVID-19 coronavirus’s vulnerability emerge from an antibody against SARS

Adaptive Biotechnologies

Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19

Applied DNA Sciences Inc

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate